Library / Repair / ARA-290
Cibinetide · IRA peptide
ARA-290
Trial
ClassInnate repair receptor peptide
Typical routes in papersSC in trials
Half-life contextShort
EvidenceSmall-fiber neuropathy / sarcoid trials
What it is
ARA-290 (cibinetide) is a tiny EPO-derived peptide designed to hit the innate repair receptor without making extra red cells.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Studied to calm neuropathic pain and small-fiber injury without the blood-thickening of EPO.
- Benefit theme: nerve comfort and tissue repair signaling.
- Not an endurance doping analog of EPO — that is the point of the design.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Selective innate repair receptor (EPOR/CD131) engagement; anti-inflammatory and neuroprotective themes without erythropoiesis.
Possible side effects / caveats
Injection reactions; still investigational. Do not treat it as a blood-builder.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Trial examples | 2–8 mg class SC in publications | Daily or several times weekly | Protocol-specific |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.